# Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

> **NCT03912415** · PHASE3 · UNKNOWN · sponsor: **Biocad** · enrollment: 316 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** BCD-100
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin (or Carboplatin)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03912415
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 316 (ESTIMATED)
- **Last updated:** 2020-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912415, "Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03912415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*